Mumbai, Sept. 18 -- Bosaya, a 60 mg/mL prefilled syringe for subcutaneous use, has been approved for the treatment of postmenopausal women and men with osteoporosis at high risk of fracture, glucocorticoid-induced osteoporosis, and bone loss caused by cancer therapies. Aukelso, a 120 mg/1.7 mL single-dose vial, has been approved for the prevention of skeletal-related events in patients with multiple myeloma or bone metastases, as well as for the treatment of giant cell tumor of bone and hypercalcemia of malignancy refractory to bisphosphonate therapy.
The USFDA has also granted provisional interchangeability designation for both products, enabling pharmacy-level substitution subject to state regulations. Clinical studies confirmed comparab...